EDITORIAL
Advice on statistical analysis, and new journal guidance for experimental design and analysis Michael J. Curtis & Darrell R. Abernethy
Correspondence The editors, Pharmacology Research & Perspectives, The Schild Plot, 16 Angel Gate, City Road, London, EC1V 2PT | UK. Tel: +44 (0) 20 7239 0171; Fax: +44 (0) 20 7417 0114; E-mail: [email protected]
The biomedical sciences sector in its wider manifestation is discussing how to address shortcomings in statistical analysis and design in research. Some pharmacology journals will change requirements for authors. In this issue of Pharmacology Research & Perspectives, Harvey Motulsky offers his personal opinion on how to improve the statistical aspect of pharmacological analysis (Motulsky 2015). During the coming months, prompted by wider concerns about failed translation (Scott et al. 2008; Mullard 2011; Curtis et al. 2015), the Pharmacology Research & Perspectives editorial team will publish new guidance on experimental design and analysis, and incorporate this into Instructions to Authors.
References Curtis MJ, Bond RA, Spina D, Ahluwalia A, Alexander SPA, Giembycz MA, et al. (2015). Time for blinded, randomized, unbiased, fully-powered studies: new journal requirements. Br J Pharmacol DOI: 10.1111/bph.12856. Motulsky H (2015). Common misconceptions about data analysis and statistics and how to avoid them. Pharmacol Res Perspect DOI: 10.1002/prp2.93. Mullard A (2011). Reliability of ‘new drug target’ claims called into question. Nat Rev Drug Discov 10:643–644. Scott S, Ktranz JE, Cole J, Lincecum JM, Thompson K, Kelly N, et al. (2008). Design, power, and interpretation of studies in the standard murine model of ALS. Amyotroph Lateral Scler 9:4–15.
ª 2014 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd, 2014 British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
| Vol. 3 | Iss. 1 | e00095 Page 1
Advice on statistical analysis, and new journal guidance for experimental design and analysis Michael J. Curtis & Darrell R. Abernethy
Correspondence The editors, Pharmacology Research & Perspectives, The Schild Plot, 16 Angel Gate, City Road, London, EC1V 2PT | UK. Tel: +44 (0) 20 7239 0171; Fax: +44 (0) 20 7417 0114; E-mail: [email protected]
The biomedical sciences sector in its wider manifestation is discussing how to address shortcomings in statistical analysis and design in research. Some pharmacology journals will change requirements for authors. In this issue of Pharmacology Research & Perspectives, Harvey Motulsky offers his personal opinion on how to improve the statistical aspect of pharmacological analysis (Motulsky 2015). During the coming months, prompted by wider concerns about failed translation (Scott et al. 2008; Mullard 2011; Curtis et al. 2015), the Pharmacology Research & Perspectives editorial team will publish new guidance on experimental design and analysis, and incorporate this into Instructions to Authors.
References Curtis MJ, Bond RA, Spina D, Ahluwalia A, Alexander SPA, Giembycz MA, et al. (2015). Time for blinded, randomized, unbiased, fully-powered studies: new journal requirements. Br J Pharmacol DOI: 10.1111/bph.12856. Motulsky H (2015). Common misconceptions about data analysis and statistics and how to avoid them. Pharmacol Res Perspect DOI: 10.1002/prp2.93. Mullard A (2011). Reliability of ‘new drug target’ claims called into question. Nat Rev Drug Discov 10:643–644. Scott S, Ktranz JE, Cole J, Lincecum JM, Thompson K, Kelly N, et al. (2008). Design, power, and interpretation of studies in the standard murine model of ALS. Amyotroph Lateral Scler 9:4–15.
ª 2014 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd, 2014 British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
| Vol. 3 | Iss. 1 | e00095 Page 1
